Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan

Trial Profile

A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Pyoderma gangrenosum
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Sep 2018 Planned End Date changed from 29 Jul 2020 to 5 May 2020.
    • 28 Aug 2018 Planned primary completion date changed from 29 Jul 2020 to 27 Aug 2019.
    • 18 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top